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Abstract 14 
Despite more than forty years of research into zona pellucida (ZP)-based vaccines, relatively little 15 
is known about their mechanism of action. Early research demonstrated precipitation of ZP 16 
glycoproteins by anti-ovarian antiserum, rendering oocytes resistant to sperm binding in vitro. 17 
Subsequent work showed significantly decreased fertilization rates following passive 18 
immunization, sparking interest in anti-ZP immunocontraception for human and animal use. The 19 
primary mechanism of action of ZP vaccines is generally considered to be an antibody mediated 20 
interference with sperm-oocyte binding and, or fertilization. However, this mechanism of action 21 
excludes the potential for ovarian dysfunction associated with anti-ZP treatment in some species. 22 
A review of relevant literature in pertinent model, domestic and wildlife species reveals a variety 23 
of previous and current hypotheses for ovarian effects following ZP-based immunization.  Ovarian 24 
dysfunction has been suggested to be a species-specific response. In addition, cytotoxic T-25 
lymphocytes and the use of Freund’s adjuvants have been suggested to play a role. Finally, the 26 
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type and extent of glycosylation of ZP antigens have been proposed to influence ovarian effects. 27 
The validity of these hypotheses is re-examined in the light of current knowledge. Further 28 
investigation of ovarian function in species believed to be resistant to the ovarian effects of anti-29 
ZP vaccines is warranted. To this end, anti-Müllerian hormone may provide a novel tool for the 30 
assessment of ovarian function during ZP-based immunocontraception, particularly in wildlife 31 
species not amenable to frequent clinical examination. 32 
 33 
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 36 
1. Introduction 37 
 38 
The zona pellucida (ZP) is a complex glycoprotein matrix surrounding the mammalian oocyte and 39 
early conceptus. Comprised of either three or four glycoproteins, the ZP plays a pivotal role in the 40 
union of oocyte and spermatozoon during mammalian fertilization, arguably the most important 41 
joining event in biology. In addition, the ZP functions in the induction of the acrosome reaction, 42 
the prevention of polyspermy and protection of the early embryo [1]. Furthermore, the ZP is 43 
intimately involved in communication between the oocyte and its surrounding granulosa cells in 44 
the developing follicle [2]. These critical functions of the ZP in reproduction and its tissue-specific 45 
nature have encouraged research into its role as an immunocontraceptive for over 40 years [3].  46 
  47 
Porcine zona pellucida (pZP) with added adjuvant remains the most common native form of the 48 
vaccine due both to the homology between the ZP proteins of many mammalian species and its 49 
availability in relatively large quantities [4, 5]. Approximately 80 zoo and wildlife species have 50 
been successfully contracepted using pZP [6]. Despite this widespread application, relatively little 51 
is reported describing the vaccine’s mechanism of action. In research aimed at humans, initial 52 
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enthusiasm for ZP-based immunocontraception waned sharply following reports of ovarian 53 
dysfunction in rabbits and non-human primates [7, 8]. A number of hypotheses regarding the 54 
causes of ovarian dysfunction during ZP-based immunocontraception have since evolved.  55 
 56 
This review re-visits initial studies describing ovarian tissue, oocytes or ZP as immunological 57 
agents, upon which our current understanding of pZP’s mechanism of action is based. In addition, 58 
several hypotheses advanced to explain ovarian dysfunction observed during ZP-based 59 
immunocontraception are re-evaluated based on relevant literature reporting on common 60 
laboratory and domestic animal species, as well as the feral horse, deer and African elephant.   61 
 62 
2. Early work on ZP antigens and antisera: a journey down memory lane 63 
 64 
Interest in immunological methods of fertility control dates back to the late 1890’s with an initial 65 
focus aimed primarily at testes and spermatozoa as immunizing agents, reviewed by Tyler [9]. 66 
Reports of antisera to ovarian homogenates blocking fertilisation processes in the sea urchin [10] 67 
and frog [11] encouraged interest in the mammalian oocyte and ovary as putative anti-fertility 68 
antigens. Initial studies demonstrated the existence of organ-specific antigens in the guinea pig 69 
ovary and testis [12, 13]. Early immunofluorescence studies further localised common antigens to 70 
the ZP, atretic follicles and the acrosome of spermatozoa [14].  71 
 72 
Ownby et al. [15] injected golden hamster ovarian homogenates combined with Freund’s 73 
complete adjuvant (FCA) into rabbits. Boosters, consisting of ovary homogenates with Freund’s 74 
incomplete adjuvant (FIA), were followed by weekly serum sampling. The antisera produced 75 
included antibodies to at least one antigen unique to the ovary, demonstrated using agar-gel 76 
diffusion plates. Super-ovulated hamster eggs exposed to rabbit anti-ovary antisera formed a 77 
precipitate in the ZP that was visible under light and phase contrast microscopy. The precipitated 78 
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ZP was found to be resistant to digestion by trypsin. Similar findings were reported by Sacco et al. 79 
[16].  80 
 81 
Anti-ovarian antiserum, added to hamster ova prior to exposure to homologous spermatozoa in 82 
vitro, interfered with sperm-oocyte binding. None of 170 pre-treated oocytes was penetrated by 83 
spermatozoa, in comparison to nearly half of 58 control oocytes [17]. The use of homogenised 84 
oocytes rather than the whole ovary as an immunogen produced similar results [18]. Despite ZP-85 
based immunocontraception being in its infancy, researchers noted the potential advantages of 86 
this method of fertility control, including reversibility and the absence of somatic side effects due 87 
to the specificity of anti-ZP antibodies [17].  88 
 89 
Jilek et al. [3], using mice passively pre-immunized with rabbit anti-mouse ovary antisera, 90 
demonstrated via immunofluorescence the presence of anti-ZP antibodies bound to oocytes 91 
aspirated from antral follicles, as well as ovulated oocytes. This showed that anti-ZP antibodies 92 
were capable of reaching the ZP in situ within the follicle. In addition, passive immunization was 93 
found to decrease fertilization rates from over 91% to below 1%. The authors concluded that the 94 
effect on fertility in vivo “seems to be a block to sperm penetration through the ZP, on which 95 
antibodies were actually detected within the follicles”.  96 
 97 
Further study of aspirated oocytes and early embryos flushed from the uterus or uterine tubes of 98 
untreated hamsters showed that anti-hamster ovary antiserum precipitated the ZP of pre-99 
ovulatory oocytes as well as early embryonic stages in vitro. In addition, precipitation of the ZP 100 
following fertilization was thought to inhibit the attachment of transferred embryos to the 101 
endometrium [19], possibly as a result of interference with embryonic hatching [20]. In a similar 102 
study in mice, anti-oocyte and anti-ZP antisera had no effect on the development of early 103 
embryos to the blastocyst stage in vitro, although a small effect on zona shedding was noted [21].  104 
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A later study in the same species found that pre-incubation with anti-ZP antiserum had no effect 105 
on early embryonic development and zona hatching in vitro, nor implantation and further 106 
development of pre-treated embryos transferred to pseudopregnant recipients, despite visible 107 
precipitation of the zonae [22]. Similarly, mice passively immunized with anti-ZP antiserum two 108 
days after mating showed no adverse effects on fertility or fecundity, and anti-ZP antisera had no 109 
effect on early embryonic development in vitro [23].  110 
 111 
From these initial studies and those that followed, hypotheses regarding ZP vaccines’ mechanism 112 
of action evolved as a primarily antibody-based interference with one or more of the following 113 
processes: sperm-oocyte binding, the acrosome reaction, sperm movement through the ZP, 114 
oocyte activation and, or the zona block; thus, at the level of the peri-ovulatory oocyte. If so, 115 
oestrous cyclicity and reproductive behaviours should remain unaffected following vaccination. 116 
This feature of pZP immunocontraception has been an important, though occasionally 117 
controversial, rationale supporting its application in species with complex social hierarchies, such 118 
as the African elephant and feral horse [24-28]. The detection, however, of ovarian dysfunction 119 
subsequent to treatment with ZP-based vaccines in some species has provided a challenge to 120 
researchers hoping to overcome this potentially undesirable outcome. During this process, a 121 
number of hypotheses regarding the cause of ovarian dysfunction have developed.  122 
 123 
 124 
3. Hypotheses explaining ovarian dysfunction during ZP-based immunocontraception 125 
 126 
3.1. “Glycosylation causes oophoritis”  127 
 128 
Glycosylation refers to the pattern of binding of distinct carbohydrate moieties to amino acids, 129 
giving rise to the glycoprotein structure of the ZP. The diverse nature of ZP glycosylation across 130 
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species may play a role in the species-specificity of sperm-zona binding [29]. Chemical de-131 
glycosylation of pZP3 was found to decrease its antigenicity and immunogenicity; precipitation of 132 
ZP in vitro by the relevant antisera was more superficial than precipitation produced using 133 
antisera to glycosylated pZP3 [30]. Consequently early workers in the field considered the de-134 
glycosylation of ZP antigens in order to negate pZP’s oophoritogenic effects.  In rabbits, the 135 
degree of glycosylation of pZP was found to correlate directly with the degree of interference 136 
with folliculogenesis, ovulation and oestrous cyclicity [31, 32]. Researchers hoped that qualitative, 137 
rather than purely quantitative, differences in the immune response to de-glycosylated versus 138 
glycosylated ZP antigens were responsible for the differences in oophoritogenic effect [32]. 139 
Subsequent trials in marmoset monkeys [33] and baboons [34] found that immunization with de-140 
glycosylated pZP3 did indeed result in lower levels of ovarian dysfunction compared to 141 
glycosylated pZP3; a result that correlated to poorer antibody responses. In addition, antisera to 142 
de-glycosylated ZP antigens provided poorer contraceptive efficacy in vitro [33]. Although now 143 
abandoned as a possible means of preventing oophoritis, glycosylation remains a factor to 144 
consider when designing synthetic vaccines. For example, Hardy et al. [35] investigated the use of 145 
mammalian versus insect expression systems in the production of a recombinant murine ZP3 146 
antigen. Recombinant ZP3 produced in a mammalian expression system caused a transient 147 
antifertility effect. However, recombinant ZP3 produced in an insect expression system had no 148 
anti-fertility effect despite evidence of an antibody response, possibly as a result of differences in 149 
glycosylation of the protein product. Furthermore, differences in glycosylation may contribute to 150 
the reduced immunogenicity associated with some synthetic vaccines, where multiple boosters 151 
have been required to maintain adequate antibody titres [36-38].   152 
 153 
3.2. “Contamination with non-ZP ovarian proteins causes ovarian dysfunction” 154 
 155 
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An early study investigating pZP immunocontraception in cynomolgus monkeys suggested that 156 
contamination may have been responsible for the ovarian dysfunction detected, as a result of 157 
immune responses directed towards extra-ZP ovarian epitopes [8]. This hypothesis currently 158 
remains a commonly advanced argument [39].  159 
 160 
Specific binding of anti-ZP antibodies within the developing ovarian follicle, primarily within the 161 
ZP, occasionally involving adjacent oolemma or granulosa cells, has been demonstrated in the 162 
rabbit [40] cat, dog, horse and African elephant [41, 42]. Similar findings have been demonstrated 163 
using immunofluorescence in both primates [43, 44] and rabbits [45].  164 
 165 
In addition, recombinant and synthetic peptide ZP antigens exclude the possibility of 166 
contamination by non-ZP ovarian proteins [46]. A review of the literature describing the use of 167 
these vaccines across a number of species includes multiple studies in which synthetic vaccines, 168 
including antigens delivered within a virus or as a DNA plasmid vaccine, are nevertheless 169 
associated with abnormalities on ovarian histology, including cellular inflammatory infiltration 170 
and, or decreased follicle numbers [38, 40, 45, 47-57]. Although these findings do not completely 171 
exclude the possibility of contamination of pZP vaccines as a cause of ovarian dysfunction, these 172 
reports suggest that oophoritis or interference with folliculogenesis may be an inherent feature of 173 
ZP-based vaccines.  174 
 175 
In addition, attempts at purification of pZP to avert ovarian dysfunction has shown limited 176 
success in primates [34, 58, 59]. In the bitch, purified pZP failed to prevent ovarian pathology, 177 
although the observed pathology was milder and seen in association with lower antibody titres 178 
than that induced by a crude pZP preparation [60, 61]. 179 
 180 
3.3. “Freund’s adjuvants are linked to ovarian dysfunction” 181 
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 182 
Freund’s complete adjuvant (FCA) consists of a water-in-oil emulsion, incorporating non-183 
metabolizable oils (paraffin oil and mannide monooleate) and heat-killed Mycobacterium 184 
tuberculosis cells. Freund’s incomplete adjuvant (FIA), generally preferred for booster 185 
vaccinations, consists of a similar water-in-oil emulsion without mycobacterial cells. Since its 186 
initial description nearly eighty years ago, initially incorporating only paraffin oil and 187 
mycobacteria (reviewed in [62]), FCA has enjoyed widespread application in immunological 188 
research due to its marked efficacy as an adjuvant. However, side effects associated with FCA, 189 
particularly granulomatous injection site reactions, have discouraged its commercial use [63].  190 
 191 
Concerns regarding false positive results to tuberculosis testing following the use of FCA led to 192 
the development of Freund’s modified complete adjuvant (FMCA), incorporating M. butyricum 193 
instead of M. tuberculosis. While most ZP-based research involving Freund’s adjuvants has 194 
employed FCA, recent research in horses and African elephants has made use of FMCA. In horses, 195 
pZP with FMCA was found to induce antibody titres consistently higher than, although statistically 196 
no different to pZP with FCA [64]. Although most researchers likely refer to FCA when discussing 197 
Freund’s adjuvants, the following discussion encompasses both FCA and FMCA.  198 
 199 
A third hypothesis within ZP-based immunocontraceptive research implicates the use of Freund’s 200 
adjuvants in the pathogenesis of ovarian dysfunction. Early studies in primates detected 201 
disturbances of ovarian function in control groups administered Freund’s adjuvant alone [59, 65]. 202 
These findings were later contradicted by investigators who reported an absence of ovarian 203 
pathology in adjuvant control groups [33, 66]. A similar lack of ovarian effects was found in 204 
rabbits administered Freund’s adjuvant only, in comparison to saline-treated controls [31, 32, 67]. 205 
 206 
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In two studies reporting a direct comparison between Freund’s and alternative adjuvants in 207 
combination with pZP, only the inclusion of Freund’s adjuvant was associated with ovarian 208 
pathology in two monkey species [66, 68]. However, the alternative adjuvants induced antibody 209 
titres that were lower, and, or diminished faster than antibody titres induced by Freund’s 210 
adjuvants.  211 
  212 
Furthermore, ovarian dysfunction or oophoritis is clearly not limited to the use of Freund’s 213 
adjuvants, having been reported in association with a number of non-Freund’s adjuvants, 214 
including alum [8, 61]; muramyl dipeptide (MDP) [34, 49, 69]; MDP with Morris adjuvant [36, 70]; 215 
squalene with Arlacel-A (and SPLS; primary vaccination) [38, 71]; MDP with squalene and Arlacel-216 
A [52]; and CP20,961 [60, 72]. 217 
 218 
3.4. “Cytotoxic T-cells cause oophoritis and ovarian dysfunction” 219 
 220 
The adaptive immune system is mediated largely by T-helper and T-cytotoxic lymphocytes. T-221 
helper (CD4+) cells recognise soluble and particulate antigens presented by professional antigen 222 
presenting cells, in association with major histocompatibility class (MHC) II molecules. In the 223 
classical endogenous pathway, intracellular-derived antigens presented in association with MHC 224 
class I molecules are recognised by cytotoxic T-lymphocytes (CD8+; CTL). An alternative pathway 225 
has been suggested, whereby dendritic cells present extracellular antigens, which could include 226 
ZP antigens, via MHC I [73]. While T-helper cells play a role in the production of antibody by B-227 
lymphocytes, CTL produce a direct cytotoxic effect. Other cells capable of cytotoxicity include 228 
members of the innate immune system such as macrophages and natural killer cells. 229 
 230 
Various authors have suggested that a CTL response may be involved in the development of 231 
oophoritis during pZP immunocontraception [1, 74-77], often citing Rhim et al. [47], Lou et al. [78] 232 
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and Lou et al. [79] despite no reference to CTL within the cited studies. Few studies have actively 233 
attempted to identify CTL responses during ZP-based immunocontraception. In mice, the 234 
infiltration of CD4+ and CD8+ T-lymphocytes was demonstrated in ovarian sections using 235 
immunohistochemistry, following infection by a murine cytomegalovirus expressing mZP3 [56]. 236 
However, the presentation of the antigen by a virus provides a direct link to the classical MHC I T-237 
cell pathway, likely contributing to the CD8+ response. Further work classifying the immune 238 
response to ZP vaccines, including the potential role of CTL in the pathogenesis of ovarian 239 
dysfunction, is warranted.  240 
 241 
What does seem clear is the link between ovarian pathology, a helper (CD4+) T-cell mediated 242 
immune response and an antibody response. Rhim et al [47] showed that the adoptive transfer of 243 
CD4+ T-cells induced an oophoritis despite the absence of any detectable antibody response. This 244 
oophoritis was described as interstitial, excluding developing follicles, and did not appear to 245 
interfere with ovarian function in mice [50]. In a subsequent study, Lou et al. [51] reported that 246 
the presence of anti-ZP antibodies redirected the cell-mediated inflammatory response from the 247 
ovarian interstitium to the developing follicles, resulting in profound interference with ovarian 248 
function [51].  249 
 250 
Furthermore, Lloyd et al. [57] found that immunoglobulin-deficient mice, incapable of mounting 251 
an antibody response but otherwise capable of normal adaptive immune responses, showed 252 
neither decreased fertility nor abnormalities on electron microscopy of ovarian sections following 253 
infection by a recombinant murine cytomegalovirus expressing murine ZP3 [57]. 254 
Immunocompetent mice infected with the same virus showed decreased fertility and fecundity, 255 
and evidence of abnormal ZP formation and vacuolisation of oocytes on electron microscopy of 256 
ovarian sections. Although it could be argued that a recombinant ZP-expressing virus would be 257 
expected to show differences in immune response mechanisms to the conventional pZP vaccine, 258 
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this study suggested a pivotal role for antibodies in the development of oophoritis during anti-ZP 259 
immunocontraception.  260 
 261 
Taken together, these studies demonstrate the roles of both CD4+ T-lymphocytes and antibodies, 262 
in unison, in ZP vaccine-induced interference with ovarian function in mice. Whether or not a 263 
similar dynamic plays a role in ovarian dysfunction in other species warrants further research.   264 
 265 
3.5. “Ovarian dysfunction is species-specific” 266 
 267 
Finally, ovarian dysfunction during ZP-based immunocontraception, characterised as a cellular 268 
oophoritis and, or interference with folliculogenesis, has been described as a species-specific 269 
complication. Antibody responses to ZP-based vaccines show some variation between individuals 270 
within a species, and likely represent variation in the overall immune response to vaccination. 271 
Reasons for individual variation in immune response include factors influencing the physiological 272 
status of the individual during or after vaccine administration, including physiological stress, 273 
nutritional status, and the presence of concurrent systemic conditions. In addition, genetic 274 
differences in immune response to immunocontraceptive vaccines have been suggested to play a 275 
role [80].  276 
 277 
Significant species differences in terms of the endurance of antibody titres have also been well 278 
documented. To illustrate this, Dall sheep maintained significant antibody titres for over three 279 
years following an initial pZP vaccination regime (primary plus booster) [81], whereas Muntjac 280 
deer required bi-annual boosters to maintain antibody levels [82].  281 
 282 
A review of nine species groups (mice, rabbits, non-human primates, dogs, cats, sheep, deer, 283 
horses and African elephants), arguably the most studied species to date in terms of ZP-based 284 
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immunocontraception, revealed evidence of abnormal cyclicity in each one of these species 285 
following treatment, with the notable exception of the cat and African elephant (Table 1). Cats 286 
are refractory to pZP, showing neither cyclic disturbances nor any effect on fertility [83, 84]. One 287 
study examining oestrous cyclicity during pZP immunocontraception (two to three years after the 288 
start of treatment) in African elephants included evidence of anoestrus in a proportion of treated 289 
cows [85]. Although this effect was possibly ascribable to seasonal effects, the lack of controls 290 
complicates any definitive conclusions.  291 
 292 
In horses, ovarian inactivity following pZP treatment, certainly in the short term, appears to have 293 
been undetected for over twenty years. An initial study of pZP in horses found no significant 294 
evidence of abnormal ovarian function following short-term treatment [86]. Similarly, Powell et 295 
al. [87] found no differences in oestrous cycle characteristics between pZP-treated and untreated 296 
mares. Although researchers noted depressed excretory steroid levels and slower reversal of 297 
infertility following prolonged (> 3 years) treatment [88, 89], the mechanism of action of pZP 298 
immunocontraception in mares as an antibody-based interference with conception at the level of 299 
the oocyte remained until recently the generally-accepted dogma in this species. Bechert et al. 300 
[90] compared two long-acting pZP vaccine formulations in mares. Treated mares demonstrated 301 
lower serum progesterone levels, smaller ovaries and fewer follicles than control mares; 93% of 302 
treated mares ceased oestrous cyclicity within four months of treatment. Similarly, six of seven 303 
mares treated with two doses of the conventional pZP vaccine demonstrated periods of 304 
anoestrus post-treatment, characterised by baseline serum progesterone levels and a lack of 305 
follicular development [39]. In part, the discrepancy between the latter two studies and other, 306 
earlier studies might be explained by differences in antigen dose rates (100 µg [39] and 200 µg of 307 
a single administered formulation [90], compared to 65 µg [91]). In addition, most trials observed 308 
feral horses with associated constraints on clinical monitoring [27].  309 
 310 
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In white-tailed deer, ongoing oestrous behaviours during pZP immunocontraception has been 311 
reported by a number of studies [92-94]. Yet, a study showing depressed progesterone levels 312 
following pZP treatment suggests that ovarian inactivity may nevertheless be a feature of pZP 313 
immunocontraception in this species [95]. The dose of pZP administered in the latter study (300 314 
to 500 µg) was higher than that reported in other deer studies (65µg; [92, 93, 96]). This, however, 315 
suggests that ovarian suppression is dose-dependent, rather than species-dependent. In a later 316 
study, fewer normal secondary follicles were detected in recently re-vaccinated does in 317 
comparison to controls and does vaccinated two years previously, although sample sizes were 318 
low [97]. A third study anticipated observing increased mating behaviour in pZP-treated does but 319 
found no differences in behaviours, including oestrus and dominance behaviours, between 320 
treated and untreated groups of fallow deer [98]. Given the similar difficulties in oestrus 321 
detection between feral horses and deer, further study of the ovarian effects of pZP in deer is 322 
warranted.  323 
 324 
In summary, ovarian suppression may be an inherent feature of effective ZP-based 325 
immunocontraception, associated with the generation of elevated antibody titres over a 326 
prolonged period of time and contributing to the vaccine’s contraceptive effect, rather than a 327 
species-specific response. However, further research to confirm this hypothesis is indicated.  328 
 329 
4. The link between antibody titres, contraceptive efficacy and ovarian dysfunction 330 
 331 
Although not an absolute rule, a recurring theme throughout the literature is the apparent link 332 
between the immunogenicity of a ZP vaccine with the antifertility capabilities of the vaccine and 333 
the presence of ovarian dysfunction. In the dog [60], sheep [99] and rabbit [7, 32, 67], ovarian 334 
pathology and contraceptive efficacy showed a direct correlation when comparing two or more 335 
alternative formulations. Similarly, in primates, significant antifertility efficacy is associated with 336 
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evidence of ovarian dysfunction [70, 71, 100]; with the converse also demonstrated (poor 337 
antifertility effect with no evidence of ovarian effects) [101, 102]. Finally, in the cat, the absence 338 
of contraceptive efficacy accompanies a consistent lack of ovarian effects [83, 84, 103].  339 
 340 
These observations support the hypothesis that ovarian dysfunction is an inherent feature, or at 341 
least a component, of the mechanism of action of ZP-based vaccines [46, 60]. To the best of the 342 
authors’ knowledge, no vaccine formulation, whether native or synthetic, has yet achieved near 343 
complete contraceptive efficacy without some evidence of ovarian effects following further 344 
study. Attempts at vaccine design, aimed at the inclusion of B-cell epitopes while excluding 345 
putative oophoritogenic T-cell epitopes, have indeed shown decreased ovarian effects but, again, 346 
limited contraceptive success [70, 79, 104-106]. To further complicate matters, ovarian effects 347 
may inadvertently be missed. Periods of ovarian dysfunction may be transient and their detection 348 
consequently dependant on the timing of sampling interventions for ovarian histology in relation 349 
to vaccine administration [61].  In addition, the difficulty associated with the detection of cellular 350 
inflammatory infiltrates in ovarian tissue sections under light microscopy has been demonstrated. 351 
In an initial study, no inflammatory infiltrate was detected in ovaries observed under light 352 
microscopy [107]. However, in a follow-up study using the same population and methodology, 353 
lymphocytic infiltration of the ovary was detected using immunohistochemistry [56]. The value of 354 
immunohistochemistry over conventional histopathology in detecting oophoritis was confirmed 355 
by Bagavant et al. [52].  356 
  357 
Possible causes of interrupted folliculogenesis, leading to ovarian atrophy and anoestrous, 358 
include immune-mediated follicular destruction and interference with normal follicle 359 
development [60]. Destruction of oocytes and follicles could occur as a result of antibody-360 
mediated complement activation. Few studies have investigated the role of complement in ZP-361 
based immunocontraception. In an early study, mice were treated with solubilized hamster ZP 362 
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followed by superovulation and the flushing of oocytes from the oviducts. Antibody and 363 
complement binding to oocytes was assessed using fluorescein-conjugated rabbit anti-mouse IgG, 364 
and rabbit anti-mouse complement C3 followed by fluorescein conjugated goat anti-rabbit IgG, 365 
respectively. In both tests, bright immunofluorescence was detected on oocytes from immunised 366 
animals, with no immunofluorescence detected on control oocytes [108]. In contrast, no 367 
complement binding was visualised in ovarian sections from immunocontracepted dogs, however 368 
the small sample size and the lack of a positive control for the complement-binding assay were 369 
major limitations to the study [61].  370 
 371 
Alternatively, or additionally, the immune response might alter ZP structure and function in 372 
developing follicles, affecting communication between the growing oocyte and its surrounding 373 
granulosa cells [109]. This scenario is mimicked in mice lacking the functional gene for connexin 374 
37, one of a family of proteins involved in intercellular communication between oocytes and 375 
granulosa cells. Folliculogenesis is inhibited in connexion 37-deficient mice. In addition, ovaries 376 
show abnormal accumulations of luteinised tissue [110], possibly resembling that described in ZP-377 
treated mice [111], rabbits [40, 45, 67] and primates [8, 36]. This mechanism may be particularly 378 
plausible in the dog, where pZP treatment caused the formation of ovarian cysts associated with 379 
prolonged oestrogen secretion [61]. 380 
 381 
5. Concluding remarks  382 
 383 
The advantages of ZP-based immunocontraception include its efficacy as a contraceptive agent in 384 
many species, safety during pregnancy, reversibility (at least in the short term) and freedom from 385 
major side effects [112]. Apart from ovarian senescence, extensive macroscopic and microscopic 386 
post mortem examinations of the major organ systems in pZP-treated mares failed to reveal any 387 
pathology that could be linked solely to pZP [90]. The vaccine can be remotely delivered, 388 
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important for use in feral species [113]. Furthermore, the protein nature of the vaccine precludes 389 
its entry into the food chain [29]. Permanent sterility, if indeed this could be induced by pZP 390 
vaccination with a degree of reliability, may be a desirable side effect in certain so-called pest 391 
species [46]. Importantly, pZP vaccination appears to show minimal adverse effects on animal 392 
welfare, particularly when compared to alternative means of population control such as culling 393 
[28]. No adverse behavioural or social effects were detected in a long-term study of pZP 394 
immunocontraception in elephants [114]. In the feral horse, pZP immunocontraception has been 395 
associated with both enhanced longevity and body condition [115]. Furthermore, the vaccine 396 
showed few significant effects on social behaviours and time budgets in horses [116, 117]; one 397 
study reported an increased frequency of reproductive behaviours and a lengthening of the 398 
breeding season, which should be considered during the management of immunocontracepted 399 
herds [118]. Further studies to confirm the lack of effects on behaviour and welfare are 400 
warranted.  401 
 402 
In most species studied, annual and sometimes biennial boosters are required if the 403 
contraceptive effect is to be maintained. From a practical point of view, particularly in free-404 
ranging species like the African elephant, this requires considerable time and resource 405 
investment. A long-acting pZP formulation which induces antibodies titres that are maintained for 406 
two years or longer after a single treatment would be a major advantage. A series of studies 407 
investigated the use of lactide-glycolide polymers to form pellets incorporating pZP. The release 408 
delay, depending on the ratios of lactide and glycolide in the pellets, was either one, three or 12 409 
months. Hand-injected pellets in combination with a conventional primary dose of pZP resulted in 410 
antibody titres that were sustained at contraceptive levels for 21 to 22 months. The contraceptive 411 
effect was evident for two years; a result which was promising [119]. An entirely different 412 
approach to achieve long-lasting antibody titres and thus contraception has been the use of a 413 
liposomal formulation consisting of lecithin and cholesterol and emulsified with FMCA, or 414 
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lyophilised and then reconstituted with FCMA [90]. Both formulations produced sustained 415 
antibody titres in mares (monitored for 22 weeks) and induced cyclic changes alluded to earlier. 416 
Moreover, the latter formulation maintained antibody titres for at least seven years in African 417 
elephant cows [120].  The emulsified formulation has previously been tested in grey seals [121] 418 
and deer [122], both producing infertility that was maintained over three years or longer. Bechert 419 
et al. [90] proposed a number of possible mechanisms that may be responsible individually or, 420 
more likely, collectively for the sustained antibody titres. These were sustained release of antigen 421 
from the injection site, increased production of long-lived plasma cells in the bone marrow and 422 
mobilisation of follicular dendritic cells within draining lymph nodes. Self-boosting by zona 423 
capsules in developing follicles was also mentioned but, in the absence of local adjuvant, seemed 424 
unlikely and would also apply to other pZP formulations. While these results are extremely 425 
encouraging, the longer term effects on ovarian function have not been investigated 426 
satisfactorily. Reversibility and thus lack of long-term ovarian effects in species like the African 427 
elephant is an extremely important feature of this treatment.  428 
 429 
The commercial availability of serum anti-Müllerian hormone (AMH) assays may provide access to 430 
a novel method of monitoring the ovarian effects of immunocontraception in females. This 431 
hormone, secreted by the granulosa cells of, primarily, preantral and early antral follicles, has 432 
been correlated to antral follicle counts and ovarian reserve in mice [123], cattle [124] and 433 
women [125]. Recently, AMH levels measured in mares during the course of one year of their 434 
immunocontraception with either pZP or GnRH vaccines were compared. While the GnRH vaccine 435 
had little effect on AMH levels, pZP suppressed serum AMH in the short term (Joonѐ et. al., in 436 
preparation). Given the proposed link between low AMH levels and ovarian suppression in these 437 
mares, AMH may prove useful in species not amenable to direct clinical examinations of their 438 
reproductive organs. Likewise, pZP vaccination may provide an exciting tool for the study of AMH 439 
and its relationship to follicular dynamics and the ovarian reserve.  440 
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 441 
In conclusion, this review suggests a re-evaluation of dogmas that have emerged within the field 442 
of ZP-based immunocontraception, regarding these vaccines’ ovarian effects. The suggestion that 443 
ovarian suppression could be an inherent feature of effective ZP-based immunocontraception, 444 
across all species, requires further investigation. Nevertheless, pZP remains a valuable, practical 445 
and humane means of population management with application in a number of mammalian 446 
species.  447 
 448 
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Table 1 757 
Overview of the literature reporting on ovarian dysfunction during zona pellucida-based immunocontraception. 758 
Species No evidence of ovarian 
dysfunction detecteda 
Evidence of ovarian dysfunction 
detecteda 
Inconclusive evidence of ovarian 
dysfunction detected 
Fertility ratesb reported for the 
relevant vaccine formulation, 
within the cited studies 
Mice [74, 104-106]   9% to 100% 
 [48, 50, 53, 55-57, 107, 111]  0% to 100%  
Rabbits [7, 54]   100% 
 [7, 31, 32, 40, 45, 54, 109]  0 – 30% 
Non-human primates [36, 37, 49, 68, 70, 100-102]   25 – 100% 
 [8, 33, 34, 36, 49, 52, 58, 59, 68-
71, 100] 
 
 0 – 50% 
Cats [83, 84, 103]   16c - 100% 
Dogs [38, 60, 72]  
 
 
 100% 
 [60, 61, 72]  0 – 34% 
Sheep [99]   100% 
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 [99]  0% 
White-tailed deer [92-94, 97]   0 – 95% 
  [95] 
 
11% 
Horses [39, 86, 87]   0 – 57% 
 [39, 88-90]  0 – 8% 
African elephants   [85] 0% 
 759 
aEvidence of ovarian dysfunction includes histological evidence of oophoritis or decreased follicle numbers, or behavioural or hormonal evidence of 760 
abnormal oestrous or menstrual cyclicity 761 
bExpressed as a proportion of the control group, where control groups are available 762 
cNot statistically significant 763 
 764 
